Epidermolysis Bullosa Acquisita following Bullous Pemphigoid, Successfully Treated with the Anti-CD20 Monoclonal Antibody Rituximab

Publisher： Karger

E-ISSN： 1421-9832|215|3|252-255

ISSN： 1018-8665

Source： Dermatology, Vol.215, Iss.3, 2007-09, pp. : 252-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidermolysis bullosa acquisita with Combined Features of Bullous Pemphigoid and Cicatricial Pemphigoid

By  

Dermatology, Vol. 198, Iss. 3, 1999-06 ,pp. : 310-313

Karger

Access to resources Recommend Favorite

Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)

By  

Dermatology, Vol. 214, Iss. 4, 2007-04 ,pp. : 310-318

Karger

Access to resources Recommend Favorite

Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus?

By  

Dermatology, Vol. 214, Iss. 4, 2007-04 ,pp. : 275-277

Karger

Access to resources Recommend Favorite

A Case of an Inflammatory Variant of Epidermolysis bullosa acquisita: Chronic Bullous Dermatosis Associated with Nonscarring Mucosal Blisters and Circulating IgG Anti-Type-VII-Collagen Antibody

By  

Dermatology, Vol. 197, Iss. 1, 1998-07 ,pp. : 58-61

Karger

Access to resources Recommend Favorite

A Case of Epidermolysis Bullosa Acquisita with Autoantibody to Anti-p200 Pemphigoid Antigen and Exfoliative Esophagitis

By  

Dermatology, Vol. 212, Iss. 4, 2006-05 ,pp. : 381-384

Karger

Access to resources Recommend Favorite